BioCentury This Week Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Jan 17, 2025
Excitement filled the air at the J.P. Morgan Healthcare Conference, with a major $15 billion acquisition deal stealing the spotlight. Participants expressed optimism amidst tricky capital markets, discussing new trends in mergers and acquisitions. The growing influence of Asian investors is reshaping collaborations in biotech. Neurology is buzzing with advancements as the FDA approves therapies based on innovative endpoints. Plus, there are fresh developments in CAR T therapies, promising an engaging landscape for biotech innovation and partnerships.
AI Snips
Chapters
Transcript
Episode notes
Market Sentiment at JPM 2025
- General optimism for M&A activity in 2025, driven by the pleasant weather and initial deals.
- Concerns remain about capital markets and the survival of smaller VC funds.
JPM 2025 Attendance
- JPM 2025 had a thinner crowd than previous years, possibly due to several factors including more focused attendance.
- Cross-border deals and Asian newcos (NUCOs) likely drew Western investors, boosting specific event attendance.
Ken Song's NUCO Model
- Ken Song's successful sale of his Rays bio to Bristol Myers and launch of a new NUCO is now a model.
- Many companies are now following this strategy, raising hundreds of millions.